New biologics to enhance the immune response against HIV for long-term remission
Novel Biologics Designed to Mobilize HIV-specific CTL for Sustained HIV Remission
This study is exploring new ways to help your immune system fight HIV by creating special proteins that can boost the activity of your T cells, with the hope of achieving long-lasting control of the virus without needing constant medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10596609 on NIH RePORTER |
What this research studies
This research focuses on developing innovative biologics that can stimulate the immune system to effectively target and eliminate HIV-infected cells. By utilizing advanced protein engineering, the study aims to create specialized proteins that mimic the functions of antigen-presenting cells, enhancing the activation of HIV-specific T cells. These biologics are designed to deliver signals that not only activate T cells but also promote their growth and differentiation, potentially leading to sustained remission of HIV without the need for ongoing antiretroviral therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and are interested in exploring options for long-term remission.
Not a fit: Patients who are not infected with HIV or those who have advanced stages of HIV/AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, allowing patients to maintain remission without continuous medication.
How similar studies have performed: Other research has shown promise in using biologics to enhance immune responses against viral infections, indicating that this approach may lead to significant advancements in HIV treatment.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Goldstein, Harris — Albert Einstein College of Medicine
- Study coordinator: Goldstein, Harris
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.